Dr Payal Kohli, a recent graduate of the Harvard Medical School, is currently a fellow in cardiovascular medicine at the University of California San Francisco.
|
Women and Heart Disease: Incidence, Prevalence, Progress, and the Future
C Noel Bairey Merz, MD and Payal Kohli, MD
, April 5, 2013
In 2012, 53% of women identified heart disease as a greater threat to their mortality than breast cancer. That’s an improvement, but we have to do better, says preventive cardiologist and noted women’s heart health expert C. Noel Bairey Merz.
DPP-4 Antagonists: Benefits, Risks, and the Future
Payal Kohli, MD and Darren K. McGuire, MD, MHSc
, February 25, 2013
Dipeptidyl peptidase-4 inhibitors, of the incretin class of antidiabets drugs, are weight neutral, avoid hypoglycemia, and result in an average reduction in HbA1c of 0.5% to 1.0%. Here, an expert on the DPP-4s and their evolution discusses pros and cons.
Lipid-lowering Injectable Antibodies: The Next Big Thing?
Payal Kohli, MD and Robert Giugliano, MD, SM
, November 28, 2012
Anti-PCSK-9 monoclonal antibodies were shown to reduce LDL-C levels up to 85% in the hardest to treat patients in a group of clinical trials reported at the AHA 2012 Scientific Sessions this month. Principal investigator Dr Robert Giuliagno highlights his study and other late breaking clinical trials, here.
AHA 2012 Highlights: Multivitamins, Omega-3s, the Polypill, and More
Payal Kohli, MD and Elliott Antman, MD
, November 19, 2012
CABG surgery outperforms PCI for multi-vessel disease in diabetes patients but daily multivitamins and omega-3s do not protect against heart disease. There was good news, bad news, and unexepected news at the AHA 2012 Scientific Sessions. CardiologyNow host Dr Payal Kohli discusses highlights with Dr Elliott Antman.
Who Needs Beta-Blockers? Analysis Raises Questions
Payal Kohli, MD and Sripal Bangalore, MD
, October 24, 2012
A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events. Here to discuss are Drs Payal Kohli and Sripal Bangalore.
Myocardial Infarction: New Meaning, Same Name
Payal Kohli, MD and Yerem Yeghiazarians, MD
, October 12, 2012
The Third Universal Definition of Myocardial Infarction incorporates use of the new ultrasensitive troponin assays and refined imaging techniques--technologies that allow detection of ever-smaller ischemic myocardial injury.
Omega-3 Fatty Acid Therapy: What Comes Next?
Deepak L. Bhatt, MD and Payal Kohli, MD
, August 21, 2012
Do omega-3 fatty acids have a place in the prevention of cardiovascular disease? Here, a short podcast interview with Harvard cardiologist Dr Deepak Bhatt on the results of the ORIGIN trial and the future of fish-oil therapy.
Systemic Inflammation and Use of Diet to Stem Disease
Payal Kohli, MD and Christopher Cannon, MD
, August 2, 2012
Systemic inflammation is the common element driving many fatal human diseases – heart disease, diabetes, cancer, and others. Here, Drs Payal Kohli and Christopher Cannon discuss research on how dietary choices can help quell the fire.
AHA/ACC Guideline Expands Antiplatelet Options
Christopher Cannon, MD
, July 25, 2012
AHA/ACC treatment guidelines for UA/NSTEMI now include ticagrelor as an option, along with clopidogrel and prasugrel, for antiplatelet therapy. Here, a short podcast pinpoints the implications for primary care.
Showing 1 - 10 of 25 results.
|
|
|
